Shares of Oscar Health Inc. (NYSE:OSCR) are trading higher Thursday morning as Wall Street analysts raised price targets following the company’s 2026 Investor Day presentation. Here’s what investors need to know.

Wall Street Bullishness Follows Investor Day Execution

A primary catalyst behind Thursday morning’s upward movement is a series of sell-side research updates published ahead of the market open. Barclays maintained an Overweight rating on Oscar Health while raising the firm’s price target to $49.

Concurrently, Baird maintained its Neutral rating while raising its price target to $33 and Stephens & Co. reiterated an Equal-Weight rating with a $34 price target.

Upgraded Full-Year 2026 Profitability Outlook

The wave of positive analyst updates follows an SEC Form 8-K filed on Wednesday, detailing material improvements to Oscar’s full-year 2026 financial guidance unveiled during its Investor Day. Management raised its expected Earnings from Operations by $100 million to a new target range of $600 million to $800 million, up from previous expectations of $500 million to $700 million.

Additionally, Oscar improved its full-year Medical Loss Ratio expectation by 50 basis points to a range of 81.0% to 82.0%, compared to its prior range of 81.5% to 82.5%, signaling stronger underwriting efficiency. Alongside the upgraded earnings metrics, the company reaffirmed its full-year 2026 total revenue guidance of $18.7 billion to $19.0 billion and an SG&A expense ratio target between 15.6% and 16.1%.

OSCR Shares Rise Thursday Morning

OSCR Price Action: Oscar Health shares were up 2.38% at $33.11 at the time of publication on Thursday. The stock is approaching its 52-week high of $34.47, according to Benzinga Pro data.

Image: Shutterstock